Daily Sepsis Research Analysis
Three studies advance sepsis science today: (1) soluble CD72 is identified as a mechanistic driver of adaptive immunosuppression in sepsis with human and murine validation; (2) cecal versus colonic microbiota differentially drive sepsis lethality via higher bacterial burden and cGAS-STING/TBK1-NF-κB activation; (3) a ferroptosis-centered, seven-gene biomarker panel for postoperative sepsis is bioinformatically derived and experimentally validated.
Summary
Three studies advance sepsis science today: (1) soluble CD72 is identified as a mechanistic driver of adaptive immunosuppression in sepsis with human and murine validation; (2) cecal versus colonic microbiota differentially drive sepsis lethality via higher bacterial burden and cGAS-STING/TBK1-NF-κB activation; (3) a ferroptosis-centered, seven-gene biomarker panel for postoperative sepsis is bioinformatically derived and experimentally validated.
Research Themes
- Immunosuppression mechanisms in sepsis
- Microbiome location-specific drivers of sepsis severity
- Ferroptosis-based diagnostics and therapeutic targets
Selected Articles
1. Soluble CD72 concurrently impairs T cell functions while enhances inflammatory response in sepsis.
In sepsis patients, soluble CD72 levels rise while cell-surface CD72 declines. Exogenous sCD72 worsens sepsis survival in mice in a dose-dependent manner by binding CD100 on T cells, entering cells, and impairing T-cell functions (including reduced CD4+ T cells), while enhancing inflammatory responses. The study positions sCD72 as a mechanistic mediator of sepsis-induced adaptive immunosuppression.
Impact: This is a mechanistic discovery linking a soluble immune regulator to sepsis-associated T-cell dysfunction with human-mouse translational validation, offering a biomarker and therapeutic target.
Clinical Implications: sCD72 could serve as a prognostic biomarker and a target to reverse immunosuppression (e.g., blocking sCD72–CD100 interaction). It also cautions against therapies that might unintentionally elevate sCD72.
Key Findings
- In sepsis patients (n=57) versus healthy controls (n=40), blood sCD72 increased while cell-surface CD72 and CD72 mRNA in immune cells decreased.
- Excess recombinant sCD72 increased mortality in CLP sepsis mice in a dose-dependent manner.
- sCD72 bound to CD100 on T cells, entered the cytoplasm, and impaired T-cell functions (including reduced CD4+ T cells), while enhancing inflammatory responses.
Methodological Strengths
- Translational design integrating human patient samples with mechanistic murine CLP models
- Use of CRISPR/Cas9 knockout, recombinant protein, flow cytometry, and imaging to define mechanism
Limitations
- Single-center patient cohort with modest sample size; external validation is needed
- Therapeutic intervention studies (e.g., sCD72 blockade) were not performed
Future Directions: Validate sCD72 as a biomarker in multicenter cohorts, map its kinetics, and develop/assess sCD72–CD100 pathway inhibitors in preclinical and early-phase clinical studies.
BACKGROUND: Sepsis is defined as multi-organ dysfunction caused by dysregulated host response to infection. This dysregulated host response includes enhanced inflammatory responses and suppressed adaptive immunity, but the molecular mechanisms behind it have not yet been elucidated. CD72, a type II transmembrane protein that is primarily expressed in B cells, was found to play an immunomodulatory role in the immune system and was associated with mortality in patients with sepsis. However, whether CD72 affects the
2. Gut microbes of the cecum versus the colon drive more severe lethality and multi-organ damage.
In a murine fecal-induced peritonitis model, cecal intestinal contents caused more lethal sepsis than colonic contents, with shorter median survival, higher multi-organ damage, and stronger systemic inflammation. Mechanistically, cecal contents carried higher bacterial burden, distinct microbial communities enriched for pathogens, and induced stronger cGAS-STING and TBK1-NF-κB signaling.
Impact: It links anatomical site-specific microbiota to sepsis severity and identifies innate immune pathways as mediators, informing risk stratification after intestinal perforation.
Clinical Implications: Perforation site (cecum vs colon) may inform early risk stratification, source control urgency, and empiric antimicrobial breadth. However, clinical translation requires human validation.
Key Findings
- Cecum-derived intestinal contents caused shorter median survival and greater multi-organ damage than colon-derived contents in mice.
- Cecal contents exhibited higher bacterial burden and a distinct microbiome enriched with potentially pathogenic taxa.
- Cecal contents triggered stronger activation of cGAS-STING and TBK1-NF-κB signaling with elevated systemic cytokines and lung inflammation.
Methodological Strengths
- Controlled comparative design with peritoneal injection of site-specific intestinal contents
- Integrated 16S rRNA sequencing, bacterial burden qPCR, histology, biochemistry, cytokines, and signaling assays
Limitations
- Preclinical mouse model with peritoneal injection may not fully recapitulate human perforation physiology
- Exact sample sizes and power calculations were not specified in the abstract
Future Directions: Validate findings in clinical cohorts of right- versus left-sided perforations, and dissect microbial taxa and host pathways (cGAS-STING/TBK1-NF-κB) amenable to targeted interventions.
Intestinal perforations lead to a high risk of sepsis-associated morbidity and multi-organ dysfunctions. A perforation allows intestinal contents (IC) to enter the peritoneal cavity, causing abdominal infections. Right- and left-sided perforations have different prognoses in humans, but the mechanisms associated with different cecum and colon perforations remain unclear. This study investigates how gut flora influences outcomes from perforations at different sites in mice. Using fecal-induced peritonitis
3. Genetic analysis of diagnostic and therapeutic potential for ferroptosis in postoperative sepsis.
Using GEO datasets and FerrDb, the authors identified 38 ferroptosis-related DEGs in postoperative sepsis and narrowed to seven biomarker genes via LASSO and SVM-RFE. They mapped 52 candidate drugs (mostly MAPK14-linked), showed immune microenvironment associations (SLC38A1, MGST1, MAPK14), built a ceRNA network, and validated six genes (five by RT-qPCR).
Impact: It provides a ferroptosis-centered diagnostic panel for postoperative sepsis with multi-cohort and experimental validation, and prioritizes druggable targets/pathways.
Clinical Implications: The 7-gene signature could inform early diagnosis/risk stratification for postoperative sepsis and guide exploration of MAPK14-related therapeutics, pending prospective validation.
Key Findings
- Identified 38 ferroptosis-related DEGs in postoperative sepsis and refined to seven biomarker genes via LASSO and SVM-RFE.
- Predicted 52 gene-targeted drugs, with many linked to MAPK14; immune infiltration analysis implicated SLC38A1, MGST1, and MAPK14.
- Constructed ceRNA networks and validated six hub genes (five confirmed by RT-qPCR in patient blood).
Methodological Strengths
- Use of complementary feature selection (LASSO and SVM-RFE) with external dataset validation
- Experimental RT-qPCR confirmation in human samples enhances translational relevance
Limitations
- Retrospective secondary analyses of public datasets; clinical heterogeneity and batch effects possible
- Lacks mechanistic/functional validation of the seven genes in sepsis models and prospective clinical validation
Future Directions: Prospective, multicenter validation of the 7-gene panel; integrate with clinical variables for predictive models; functional studies of MAPK14/SLC38A1/MGST1 and drug testing.
BACKGROUND: Ferroptosis is a new form of iron-dependent cell death that is closely associated with sepsis. However, few studies have investigated the diagnostic and therapeutic potential for ferroptosis-related genes (FRGs) among postoperative sepsis. METHODS: The GSE131761 dataset was used to identify differentially expressed FRGs (DE-FRGs). KEGG and GO analyses were subsequently performed. LASSO and SVM-RFE methods were applied for identifying genetic biomarkers for sepsis. Gene set enrichment analysis (GSEA) and gene set variation analysis (GSVA) were applied for exploring the biological properties of the DEGs. CIBERSORT was applied to analyse immune cell infiltration. DGldb was employed for predicting potential target drugs for the DEGs. Competing endogenous RNA (ceRNA) networks were constructed to analyse the regulatory patterns of the DEGs. The expression of hub genes was validated based on GSE26440 dataset. The bioinformatics analysis was carried out with R software (version 4.1.2). Blood from sepsis patients and healthy controls was collected and the expression of hub genes was experimentally verified by real-time quantitative polymerase chain reaction (RT-qPCR). RESULTS: 38 sepsis-associated DE-FRGs were assessed via Gene Expression Omnibus (GEO) and Ferroptosis database (FerrDb), and the gene function analysis showed that they were closely related to inflammatory response and autophagy regulation. Subsequently, SVM-RFE and LASSO methods determined 7 marker genes. GSEA suggested that these marker genes may be involved in regulating several biological pathways. Furthermore, 52 gene-targeted drugs were identified in this study, the vast majority of which were associated with MAPK14. CIBERSORT analysis suggested that SLC38A1, MGST1, and MAPK14 may be involved in immune microenvironment alterations. We revealed the potential complex regulatory relationship by constructing a ceRNA network based on marker genes. Finally, 6 genes were validated in the validation set, with 5 of them further confirmed through RT-qPCR. CONCLUSION: Seven genes associated with ferroptosis are screened from postoperative sepsis samples. The expression of these genes has high diagnostic validity for sepsis and may serve as potential diagnostic biomarkers. This study gives an entrance point to uncover the underlying mechanisms of sepsis.